A whopping 80 percent of enterprises are investing today in AI, but one in three business leaders believe their company will need to invest more over the next 36 months to keep pace with competitors. At the same time, enterprises are anticipating significant barriers to adoption and are looking to strategize against those issues by creating a new C-suite position, the Chief AI Officer (CAIO), to streamline and coordinate AI adoption. These results come from a survey of 260 large organizations that operate globally, conducted by leading technology industry market research firm Vanson Bourne on behalf of Teradata (NYSE: TDC), the leading data and analytics company.
“There is an important trend emerging evident in this report — enterprises today see AI as a strategic priority that will help them outpace the competition in their respective industries,” says Atif Kureishy, Vice President, Emerging Practices at Think Big Analytics, a Teradata company. “But to leverage the full potential of this technology and gain maximum ROI, these businesses will need to revamp their core strategies so AI has an embedded role from the data center to the boardroom.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8075951-teradata-state-of-artificial-intelligence-ai-for-enterprises/
Today, the American Immigration Lawyers Association (AILA) issued a report card on President Obama's immigration efforts over the past seven years and made recommendations for how to reform immigration in his last year.
“In recent days and weeks he has shown leadership in protecting refugees from Syria,” said AILA President Victor Nieblas Pradis. “But until recently, the president's response was timid and he still plans to resettle only 10,000 Syrian refugees this year. He can save many more lives by setting his target at 100,000 Syrian refugees.”
“In our own hemisphere, when Central American individuals and families, including young children, arrived at our southern border seeking refuge from the horrific violence plaguing those countries, the president should have protected them, but instead, he treated them as a border threat. The president should acknowledge that the situation in Central America is a humanitarian crisis and use every tool at his disposal to protect those fleeing. Most important he should stop detaining thousands of families.”
“The reforms to the legal immigration system he promised a year ago have moved forward at a glacial pace, earning him an incomplete. He can benefit the economy enormously by implementing plans to encourage research, development and entrepreneurial start-ups.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7683151-aila-national-immigration-report-card/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
The public is generally satisfied with cancer research progress over the past 20 years. However, they believe it takes too long for new cancer medicines to reach patients and that their countries invest too little in fighting cancer. Most fear that the current economic crisis will slow cancer research progress. This is according to the PACE Cancer Perception Index: A Six-Nation, Public Opinion Survey of Cancer Knowledge and Attitudes, released today in advance of World Cancer Day, which is recognized on February 4, 2013.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60140-lilly-oncology-pace-cancer-perception-index
On the eve of World Cancer Day 2015, amidst the ongoing cost-of-cancer-care debate, PACE (Patient Access to Cancer care Excellence), a Lilly Oncology initiative, is launching the PACE Continuous Innovation Indicators™ (CII). CII is the first evidence-based, customizable online tool to review progress against cancer over time—initially covering 12 cancer types. The purpose of the tool is to inform public policy reforms and other efforts to accelerate continuous innovation against cancer.
“We have seen tremendous progress in cancer treatment and care during the past decades, and continuous innovation, with one discovery building on another, is responsible for most of it,” said John C. Lechleiter, Ph.D., Chairman, President, and Chief Executive Officer of Eli Lilly and Company (NYSE:LLY). “To keep the momentum going, we need policies that support continuous innovation, but first we need a deeper understanding of the innovations that have occurred, and where we need to be.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7419451-eli-lilly-oncology-pace/
As entrepreneurs struggle to find desirable investments that also allow them to have an impact on the future of our country, Primrose Schools invites them to explore the benefits of opening a high-quality Primrose preschool in their communities. As the nation’s leading early education franchise company, Primrose currently has more than 350 locations in 29 states and is growing across the country.
Financial forecasters and economic developers alike point to early education as a stable investment that yields strong returns. A recent report by Child Care Aware shows that the high-quality early education industry generates a return of more than $8 for every $1 spent, meaning the returns of providing early education for children positively impact the economic development of communities and future workforce development. Last year, IBIS World reported that the industry reached a record high of $47.8 billion and is expected to continue to grow at an even faster pace than the overall child services market.
To view the multimedia release go to:
https://www.multivu.com/players/English/8014454-primrose-schools-open-your-own-school/
